it’s with pleasure to inform you that LDN has launched today its latest development – the first commercial immunoassay worldwide for the quantitative determination of

3-Methoxytyramine (3-MT)

in human plasma.

The determination of normetanephrine and metanephrine in plasma is a sensitive test for diagnosing phaechromocytoma and paragangliomas (PPGLs) – but it does not provide the possibility to detect dopamine-producing tumours. Dopamine and especially its O-methylated metabolite 3-MT are reliable biomarkers for the detection of malignant PPGLs.

This new assay compares with excellence to the LC-MS/MS method (please refer to the flyer attached) and offers an accurate, selective and sensitive measurement of 3-MT.

The assay itself (catalogue number: BA R-8800; please refer to the instructions for use in the attachment) uses an elegant extraction procedure followed by a competitive RIA.


With this new assay LDN is now able to offer the most comprehensive panel worldwide for the measurement of PPGL-relevant parameters including:

  • Urinary Metanephrine/Normetanephrine (free and total; ELISA&RIA)
  • Plasma Metanephrine/Normetanephrine (ELISA&RIA)
  • Catecholamines in plasma and urine (ELISA&RIA)
  • Chromogranin A (ELISA)


For more information, please  contact us at